Compare WST & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | EXAS |
|---|---|---|
| Founded | 1923 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7B | 19.3B |
| IPO Year | N/A | N/A |
| Metric | WST | EXAS |
|---|---|---|
| Price | $249.11 | $102.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $338.00 | $84.27 |
| AVG Volume (30 Days) | 744.1K | ★ 2.1M |
| Earning Date | 02-12-2026 | 02-18-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ 0.17 | N/A |
| EPS | ★ 6.75 | N/A |
| Revenue | $3,017,900,000.00 | ★ $3,082,033,000.00 |
| Revenue This Year | $6.97 | $19.40 |
| Revenue Next Year | $6.27 | $13.51 |
| P/E Ratio | $37.79 | ★ N/A |
| Revenue Growth | 4.92 | ★ 14.47 |
| 52 Week Low | $187.43 | $38.81 |
| 52 Week High | $348.90 | $102.66 |
| Indicator | WST | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 80.22 |
| Support Level | $244.70 | $102.00 |
| Resistance Level | $281.55 | $102.56 |
| Average True Range (ATR) | 10.24 | 0.33 |
| MACD | -3.19 | -0.54 |
| Stochastic Oscillator | 8.19 | 72.49 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.